zydelig
gilead sciences ireland uc - idelalisib - lymphoma, non-hodgkin; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, other antineoplastic agents - zydelig is indicated in combination with an anti‑cd20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (cll):who have received at least one prior therapy, oras first line treatment in the presence of 17p deletion or tp53 mutation in patients who are not eligible for any other therapies. zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (fl) that is refractory to two prior lines of treatment.
aridol
pharmaxis europe limited - mannitol - inhalasjonspulver, hard kapsel - 20 mg / 40 mg / 10 mg / 0 mg / 5 mg
flutide 50 mikrog/ dose
glaxosmithkline as - flutikasonpropionat - inhalasjonsaerosol, suspensjon - 50 mikrog/ dose
flutide 125 mikrog/ dose
glaxosmithkline as - flutikasonpropionat - inhalasjonsaerosol, suspensjon - 125 mikrog/ dose
flutide 250 mikrog/ dose
glaxosmithkline as - flutikasonpropionat - inhalasjonsaerosol, suspensjon - 250 mikrog/ dose
flutide 50 mikrog/ dose
glaxosmithkline as - flutikasonpropionat - inhalasjonspulver, dosedispensert - 50 mikrog/ dose
flutide 100 mikrog/ dose
glaxosmithkline as - flutikasonpropionat - inhalasjonspulver, dosedispensert - 100 mikrog/ dose
flutide 250 mikrog/ dose
glaxosmithkline as - flutikasonpropionat - inhalasjonspulver, dosedispensert - 250 mikrog/ dose
flutide 500 mikrog/ dose
glaxosmithkline as - flutikasonpropionat - inhalasjonspulver, dosedispensert - 500 mikrog/ dose
copiktra
secura bio limited - duvelisib - leukemia, lymphocytic, chronic, b-cell; lymphoma, follicular - antineoplastiske midler - copiktra monotherapy is indicated for the treatment of adult patients with: relapsed or refractory chronic lymphocytic leukaemia (cll) after at least two prior therapies. follicular lymphoma (fl) that is refractory to at least two prior systemic therapies.